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Methicillin-resistant Staphylococcus aureus (MRSA) infec-
tions cause great concern in intensive care units (ICUs) [1].
Although strict infection control protocols have reduced
staphylococcal colonization, the ICU still represents a reser-
voir for MRSA infections, playing a role in their circulation
to multiple wards and hospitals [2–4]. In critically ill pa-
tients, lack of adequate treatment may lead to increased
mortality [1]. For this reason, broad-spectrum antimicrobial
therapy is often justified among critically ill patients.
We retrospectively analyzed the characteristics of S.
aureus bloodstream infections (SA-BSI) from two Italian
University hospitals during 2010–2014. A total of 17/337
(5 %) were ICU patients; of these, 16 (94 %) had MRSA-BSI
compared with 36 % (116/320) from other wards (P <
0.001). Lower adequate first-line therapy (defined as therapy
administered within 48 h of the positive blood culture and
effective against a susceptible pathogen) and infectious dis-
eases (ID) specialist consultation were documented in ICU
versus non-ICU patients (18 versus 60 % and 53 versus
24 %, P < 0.001 and P = 0.02, respectively). When only
MRSA infections were considered, adequate therapy and
ID consultation remained more common in non-ICU
patients (Table 1; difference not significant). Inadequate
therapy for non-ICU and ICU patients was mainly associ-
ated with beta-lactam use (62/104 versus 10/12, respect-
ively, P = 0.19). Patients with MRSA infections in the ICU
displayed a lower Charlson score, longer hospitalizations,
higher rates of nosocomial infections, endocarditis, and
central venous catheter (CVC) and urinary catheter place-
ment. Source control, including CVC removal, was signifi-
cantly higher in ICU versus non-ICU patients (Table 1). A
stepwise logistic regression analysis identified ICU stay
(odds ratio (OR) 19.5, 95 % confidence interval (CI) 3.4–
384.2, P < 0.001), presence of intravascular devices other
than CVCs for over 72 h (OR 3.5, 95 % CI 1–13.2, P =
0.04), and pulmonary source of infection (OR 3.2, 95 % CI
1.2–9.4, P = 0.02) as factors associated with MRSA-BSI.
Overall crude 7- and 30-day mortality was similar for
MRSA- (Table 1) and SA-BSI (13 versus 18 % in non-ICU
and 25 versus 29 % in ICU patients, respectively). Multi-
variate analysis identified as independent factors for 7-day
mortality among patients with MRSA an inadequate tar-
geted treatment (OR 0.19, 95 % CI 0.04–0.86, P = 0.03),
absence of ID consultation (OR 0.17, 95 % CI 0.04–0.6, P =
0.004), and occurrence of endocarditis (OR 4.8, 95 % CI
1.4–17.5, P = 0.01) or septic shock (OR 15.9, 95 % CI 4.6–
66.7, P < 0.001). High Charlson score (OR 1.25, 95 % CI
1.1–1.5, P = 0.004) and septic shock (OR 2.8, 95 % CI 1.0–
7.9, P = 0.04) were significantly associated with 30-day
mortality.
The prevalence of MRSA varies widely by geographic re-
gion [5]. In our report, overall MRSA rates were compar-
able to those reported in Italy (33.6 %) by the European
Antimicrobial Resistance Surveillance (EARS) in 2014 [5].
Our data highlight that inadequate MRSA first-line
therapy can occur in clinical settings known to be at
high risk for multi-drug resistant (MDR) infections.
Low ID involvement and a priority towards multidrug-
resistant Gram-negatives are possible reasons for a re-
duced first-line use of anti-MRSA compounds in the
ICU. Although ICU patients displayed higher rates of
inadequate first-line therapy and risk factors associ-
ated with increased mortality (e.g., reduced ID con-
sultation and endocarditis) [6], overall mortality was
comparable between groups. This may be related to a
limited number of patients with septic shock in the
ICU group; furthermore, low Charlson scores and
higher source control in the ICU group compared
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with the non-ICU group may have contributed to
achieve positive outcomes.
In conclusion, our study draws attention to an alarming
proportion of first-line inadequate therapy among patients
with SA-BSI in the ICU. In this setting, the use of protocols
including anti-MRSA agents in patients at risk for
Staphylococcus aureus bacteremia (SAB) should be recom-
mended, and clinicians must retain a high level of suspicion
for MRSA infections in order to select an appropriate early
antimicrobial treatment and ultimately reduce mortality.
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